SE512633C2 - Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat - Google Patents

Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat

Info

Publication number
SE512633C2
SE512633C2 SE9702657A SE9702657A SE512633C2 SE 512633 C2 SE512633 C2 SE 512633C2 SE 9702657 A SE9702657 A SE 9702657A SE 9702657 A SE9702657 A SE 9702657A SE 512633 C2 SE512633 C2 SE 512633C2
Authority
SE
Sweden
Prior art keywords
hyaluronidase
medicament
manufacture
inflammatory cell
hyaluronan
Prior art date
Application number
SE9702657A
Other languages
English (en)
Swedish (sv)
Other versions
SE9702657L (sv
SE9702657D0 (sv
Inventor
Cecilia Johnsson
Gunnar Tufveson
Roger Haellgren
Bengt Gerdin
Original Assignee
Cecilia Johnsson
Gunnar Tufveson
Roger Haellgren
Bengt Gerdin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cecilia Johnsson, Gunnar Tufveson, Roger Haellgren, Bengt Gerdin filed Critical Cecilia Johnsson
Priority to SE9702657A priority Critical patent/SE512633C2/sv
Publication of SE9702657D0 publication Critical patent/SE9702657D0/xx
Priority to DE69835210T priority patent/DE69835210T2/de
Priority to ES98921978T priority patent/ES2267186T3/es
Priority to PCT/SE1998/000831 priority patent/WO1999002181A1/en
Priority to EP98921978A priority patent/EP0994719B1/en
Priority to AU74618/98A priority patent/AU741770B2/en
Priority to CA002296581A priority patent/CA2296581A1/en
Priority to JP50850999A priority patent/JP2002509542A/ja
Priority to AT98921978T priority patent/ATE332706T1/de
Priority to US09/462,362 priority patent/US6572855B1/en
Publication of SE9702657L publication Critical patent/SE9702657L/
Priority to NO20000098A priority patent/NO20000098L/no
Publication of SE512633C2 publication Critical patent/SE512633C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
SE9702657A 1997-07-09 1997-07-09 Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat SE512633C2 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9702657A SE512633C2 (sv) 1997-07-09 1997-07-09 Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat
US09/462,362 US6572855B1 (en) 1997-07-09 1998-05-06 Use of hyaluronidase in the manufacturing of a drug for the treatment of inflammation
EP98921978A EP0994719B1 (en) 1997-07-09 1998-05-06 Use of hyaluronidase in the manufacturing of a drug for the treatment of inflammation
ES98921978T ES2267186T3 (es) 1997-07-09 1998-05-06 Uso de hialuronidasa en la fabricacion de un farmaco para el tratamiento de la inflamacion.
PCT/SE1998/000831 WO1999002181A1 (en) 1997-07-09 1998-05-06 Use of hyaluronidase in the manufacturing of a drug for the treatment of inflammation
DE69835210T DE69835210T2 (de) 1997-07-09 1998-05-06 Verwendung von hyaluronidase zur herstellung eines arzneimittels zur behandlung von entzündungen
AU74618/98A AU741770B2 (en) 1997-07-09 1998-05-06 Use of hyaluronidase in the manufacturing of a drug for the treatment of inflammation
CA002296581A CA2296581A1 (en) 1997-07-09 1998-05-06 Use of hyaluronidase in the manufacturing of a drug for the treatment of inflammation
JP50850999A JP2002509542A (ja) 1997-07-09 1998-05-06 炎症治療用薬剤の製造におけるヒアルロニダーゼの使用
AT98921978T ATE332706T1 (de) 1997-07-09 1998-05-06 Verwendung von hyaluronidase zur herstellung eines arzneimittels zur behandlung von entzündungen
NO20000098A NO20000098L (no) 1997-07-09 2000-01-07 Anvendelse av hyaluronidase ved fremstillingen av et medikament for behandling av inflammasjon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702657A SE512633C2 (sv) 1997-07-09 1997-07-09 Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat

Publications (3)

Publication Number Publication Date
SE9702657D0 SE9702657D0 (sv) 1997-07-09
SE9702657L SE9702657L (sv) 1999-01-10
SE512633C2 true SE512633C2 (sv) 2000-04-17

Family

ID=20407703

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9702657A SE512633C2 (sv) 1997-07-09 1997-07-09 Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat

Country Status (11)

Country Link
US (1) US6572855B1 (no)
EP (1) EP0994719B1 (no)
JP (1) JP2002509542A (no)
AT (1) ATE332706T1 (no)
AU (1) AU741770B2 (no)
CA (1) CA2296581A1 (no)
DE (1) DE69835210T2 (no)
ES (1) ES2267186T3 (no)
NO (1) NO20000098L (no)
SE (1) SE512633C2 (no)
WO (1) WO1999002181A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026666A1 (de) * 2000-05-29 2001-12-20 Gunther Burgard Verwendung von Hyaluronidase zur Prophylaxe und Behandlung von Herz-Kreislauf-Erkrankungen
US6682904B1 (en) * 2002-08-15 2004-01-27 Deliatroph Pharmaceuticals, Inc. Specific inhibitors of hyaluronidase 2, and methods of identifying and using same
JP4464395B2 (ja) 2003-03-05 2010-05-19 ヘイローザイム インコーポレイテッド 可溶性ヒアルロニダーゼ糖タンパク質（ｓＨＡＳＥＧＰ）、その調製プロセス、使用およびそれを含む薬学的組成物
WO2008149428A1 (ja) * 2007-06-05 2008-12-11 Glycoscience Laboratories, Inc. 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤
EP2285402A2 (en) 2008-04-14 2011-02-23 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
US8784896B2 (en) 2012-09-17 2014-07-22 Biopep Solutions, Inc Antioxidant therapy with a whole, leech saliva extract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504025D0 (en) * 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
US5747027A (en) * 1995-04-07 1998-05-05 The Regents Of The University Of California BH55 hyaluronidase
US5958750A (en) 1996-07-03 1999-09-28 Inctye Pharmaceuticals, Inc. Human hyaluronidase

Also Published As

Publication number Publication date
ATE332706T1 (de) 2006-08-15
EP0994719B1 (en) 2006-07-12
EP0994719A1 (en) 2000-04-26
JP2002509542A (ja) 2002-03-26
NO20000098D0 (no) 2000-01-07
SE9702657L (sv) 1999-01-10
AU741770B2 (en) 2001-12-06
DE69835210T2 (de) 2007-07-05
SE9702657D0 (sv) 1997-07-09
AU7461898A (en) 1999-02-08
CA2296581A1 (en) 1999-01-21
ES2267186T3 (es) 2007-03-01
WO1999002181A1 (en) 1999-01-21
NO20000098L (no) 2000-01-07
US6572855B1 (en) 2003-06-03
DE69835210D1 (de) 2006-08-24

Similar Documents

Publication Publication Date Title
Harris et al. Verapamil protects against progression of experimental chronic renal failure
Gordon et al. Vitamin C in health and disease: a companion animal focus
Ketterer et al. The pituitary growth hormone and metabolic processes
Friedman et al. Pituitary growth hormone essential for regulation of serum cholesterol
SCHNEIDER et al. Insulin-treatment of diabetic rats: effects on duodenal calcium absorption
Faust et al. Effect of lipoic acid on cyclophosphamide-induced diabetes and insulitis in non-obese diabetic mice
Sudhir et al. Potassium preserves endothelial function and enhances aortic compliance in Dahl rats.
GB2223403A (en) The treatment of disorders occurring on transplantation.
SE512633C2 (sv) Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat
EP2085094A2 (de) Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
US5955111A (en) Methods and compositions for inducing production of stress proteins
US4670467A (en) Method of controlling graft versus host reaction
CA2507595A1 (en) Use of dextran sulfate in the treatment of instant blood-mediated inflammatory reaction
Beher et al. Effects of psyllium hydrocolloid on bile acid metabolism in normal and hypophysectomized rats
US10406205B1 (en) Method for curing diabetes and damaged organs and tissues affected by diabetes
EP0532706A1 (en) REDUCING CARDIOVASCULAR VESSEL CLOSURE WITH ASCORBATE AND LIPOPROTEIN BINDING INHIBITORS (A).
Deaciuc et al. Calcium content in liver and heart and its intracellular distribution in liver during endotoxicosis and sepsis in rats
KR20030079783A (ko) 만성 질환성 빈혈 및 기능적 철 결핍증의 치료를 위한사람 트랜스페린
JPH09506115A (ja) 細胞毒性薬の副作用を軽減するためのトランスフェリン組成物
Hall et al. Enhancement of somatotrophic hormone-induced hypertensive cardiovascular disease by stress
McGeachin et al. The in vivo effects of puromycin on amylase levels in the serum, liver, salivary glands, and pancreas of the rat
JPH05320043A (ja) リポポリサッカライド捕捉剤
Balestri et al. Chronic urea intoxication in dogs
CA2262637C (en) Use of hyaluronidase
Kline et al. PHOSPHOLIPID METABOLISM IN RAT LIVER SLICES: EFFECT OF HYPOPHYSECTOMY AND ADRENALECTOMY ON THE LABELLING OF PHOSPHOLIPIDS WITH ACETATE-1-C14

Legal Events

Date Code Title Description
NUG Patent has lapsed